[go: up one dir, main page]

LU91133I9 - Novel quinuclidine derivatives and medicinal composition thereof - Google Patents

Novel quinuclidine derivatives and medicinal composition thereof

Info

Publication number
LU91133I9
LU91133I9 LU91133C LU91133C LU91133I9 LU 91133 I9 LU91133 I9 LU 91133I9 LU 91133 C LU91133 C LU 91133C LU 91133 C LU91133 C LU 91133C LU 91133 I9 LU91133 I9 LU 91133I9
Authority
LU
Luxembourg
Prior art keywords
quinuclidine derivatives
medicinal composition
diseases
novel quinuclidine
novel
Prior art date
Application number
LU91133C
Other languages
English (en)
Other versions
LU91133I2 (fr
Inventor
Yasuo Isomura
Makoto Takeuchi
Ryo Naito
Masahiko Hayakawa
Yoshinori Okamoto
Yasuhiro Yonetoku
Ken Ikeda
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18194699&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91133(I9) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of LU91133I2 publication Critical patent/LU91133I2/fr
Publication of LU91133I9 publication Critical patent/LU91133I9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • C07D221/12—Phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K19/00—Liquid crystal materials
    • C09K19/04—Liquid crystal materials characterised by the chemical structure of the liquid crystal components, e.g. by a specific unit
    • C09K19/06—Non-steroidal liquid crystal compounds
    • C09K19/34—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring
    • C09K19/3441—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring having nitrogen as hetero atom
    • C09K19/3444—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring having nitrogen as hetero atom the heterocyclic ring being a six-membered aromatic ring containing one nitrogen atom, e.g. pyridine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Materials Engineering (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
  • Tea And Coffee (AREA)
LU91133C 1994-12-28 2005-01-28 Novel quinuclidine derivatives and medicinal composition thereof LU91133I9 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP32704594 1994-12-28
PCT/JP1995/002713 WO1996020194A1 (fr) 1994-12-28 1995-12-27 Nouveaux derives de quinuclidine et composition pharmaceutique les contenant

Publications (2)

Publication Number Publication Date
LU91133I2 LU91133I2 (fr) 2005-03-29
LU91133I9 true LU91133I9 (en) 2018-08-01

Family

ID=18194699

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91133C LU91133I9 (en) 1994-12-28 2005-01-28 Novel quinuclidine derivatives and medicinal composition thereof

Country Status (24)

Country Link
US (2) US6017927A (fr)
EP (1) EP0801067B1 (fr)
JP (1) JP3014457B2 (fr)
KR (1) KR100386487B1 (fr)
CN (1) CN1045601C (fr)
AT (1) ATE233761T1 (fr)
AU (1) AU695616B2 (fr)
CA (1) CA2208839C (fr)
DE (2) DE69529844T2 (fr)
DK (1) DK0801067T3 (fr)
ES (1) ES2193208T3 (fr)
FI (1) FI115631B (fr)
FR (1) FR04C0032I2 (fr)
HU (1) HU223778B1 (fr)
LU (1) LU91133I9 (fr)
MX (1) MX9704880A (fr)
NL (1) NL300141I1 (fr)
NO (4) NO2005012I1 (fr)
NZ (1) NZ298144A (fr)
PL (1) PL182344B1 (fr)
PT (1) PT801067E (fr)
RU (1) RU2143432C1 (fr)
TW (1) TW305842B (fr)
WO (1) WO1996020194A1 (fr)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008128028A2 (fr) * 2007-04-11 2008-10-23 Dr. Reddy's Laboratories Ltd. Compositions à base de solifénacine
US20100137358A1 (en) * 1996-11-05 2010-06-03 Dr. Reddy's Laboratories Ltd. Solifenacin compositions
FR2772378B1 (fr) * 1997-12-12 2000-02-04 Synthelabo Derives d'imidazole, leur preparation et leur application en therapeutique
US7214687B2 (en) 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
JP2001316670A (ja) * 2000-05-02 2001-11-16 Dainippon Ink & Chem Inc 液晶組成物
DK1300407T4 (da) * 2000-06-27 2011-09-05 S A L V A T Lab Sa Carbamater afledt af arylalkylaminer
AU2002228015B2 (en) * 2000-12-22 2007-08-23 Almirall, S.A. Quinuclidine carbamate derivatives and their use as M3 antagonists
EP1353919B1 (fr) 2000-12-28 2006-07-26 Almirall Prodesfarma AG Nouveaux derives de quinuclidine et compositions medicinales contenant ces derniers
ES2359719T3 (es) * 2001-07-10 2011-05-26 Astellas Pharma Inc. Composición farmacéutica comprendiendo quinuclidin-3'-il 1-fenil-1,2,3,4-tetrahidroisoquinolin-2-carboxilato para el tratamiento de la cistitis instersticial y/o la prostatitis no bacteriana.
IL162596A0 (en) * 2001-12-20 2005-11-20 S A L V A T Lab Sa 1-Alkyl-1-azoniabicyclo Ä2.2.2Ü octane carbamate derivatives and their use as muscarinic receptor ntagonists
JP4466370B2 (ja) * 2002-06-07 2010-05-26 アステラス製薬株式会社 過活動膀胱治療剤
ES2203327B1 (es) 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2204295B1 (es) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
ATE419236T1 (de) 2002-07-08 2009-01-15 Ranbaxy Lab Ltd 3,6-disubstituierte azabicyclo-3.1.0 hexan- derivate als muscarinische rezeptorantagonisten
WO2004014853A1 (fr) 2002-07-31 2004-02-19 Ranbaxy Laboratories Limited Derives 3,6-disubstitues d'azabicyclo [3.1.0]hexane utilises comme antagonistes des recepteurs muscariniques
EP1545508A4 (fr) 2002-08-09 2009-11-25 Ranbaxy Lab Ltd Derives d'azabicyclo ¬3.1.0 hexane 3,6-disubstitues, utiles en tant qu'agonistes de recepteurs muscariniques
JP2006501236A (ja) 2002-08-23 2006-01-12 ランバクシー ラボラトリーズ リミテッド ムスカリン性レセプター拮抗薬としてのフルオロおよびスルホニルアミノ含有３，６−二置換アザビシクロ（３．１．０）ヘキサン誘導体
MXPA05003398A (es) * 2002-10-29 2005-06-22 Pharmacia & Upjohn Co Llc Compuestos de amonio cuaternario.
ATE400553T1 (de) 2002-12-10 2008-07-15 Ranbaxy Lab Ltd 3,6-disubstituierte azabicyclo 3.1.0 - hexanderivative als antagonisten des muscarinrezeptors
EP1480631B1 (fr) * 2002-12-20 2007-08-01 Dynogen Pharmaceuticals Inc. Methodes de traitement de troubles de la vessie non douloureux au moyen de modulateurs de la sous unite alpha-2-delta- du canal calcique
US7501443B2 (en) 2002-12-23 2009-03-10 Ranbaxy Laboratories Limited Flavaxate derivatives as muscarinic receptor antagonists
EP1583741A1 (fr) 2002-12-23 2005-10-12 Ranbaxy Laboratories, Limited Derives de 1-substitues-3-pyrrolidines comme antagonistes de recepteurs muscariniques
US7488748B2 (en) 2003-01-28 2009-02-10 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
WO2004084879A1 (fr) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. Methodes de traitement de troubles des voies urinaires inferieures utilisant des modulateurs des muscles lisses et des modulateurs des canaux calciques de la sous-unite $g(a)2$g(d)
EP1618091A1 (fr) 2003-04-09 2006-01-25 Ranbaxy Laboratories, Ltd. Derives d'azabicyclo hexane substitues en tant qu'antagonistes de recepteurs muscariniques
EP1615887A1 (fr) 2003-04-10 2006-01-18 Ranbaxy Laboratories, Ltd. Derives d'azabicyclo hexanes en tant qu'antagonistes des recepteurs muscariniques
JP2006514978A (ja) 2003-04-10 2006-05-18 ランバクシー ラボラトリーズ リミテッド ムスカリン受容体アンタゴニストである置換アザビシクロヘキサン誘導体
EA009387B1 (ru) 2003-04-11 2007-12-28 Рэнбакси Лабораториз Лимитед Азабициклические производные в качестве антагонистов мускаринового рецептора
WO2004091597A2 (fr) * 2003-04-15 2004-10-28 Pharmacia & Upjohn Company Llc Procede pour traiter le syndrome du colon irritable
US20050175689A1 (en) * 2003-10-27 2005-08-11 Yamanouchi Pharmaceutical Co., Ltd. Coated fine particles containing drug for intrabuccally fast disintegrating tablet
US20080287680A1 (en) * 2004-02-09 2008-11-20 Astellas Pharma Inc. Solifenacin Succinate-Containing Composition
WO2005077364A1 (fr) * 2004-02-18 2005-08-25 Yamanouchi Pharmaceutical Co., Ltd. Préparation transdermique de solifénacine et procédé d'amélioration de la perméabilité transdermique de celle-ci
CA2560080A1 (fr) * 2004-03-16 2005-09-22 Astellas Pharma Inc. Composition contenant de la solifenacine
JPWO2005087231A1 (ja) 2004-03-16 2008-01-24 アステラス製薬株式会社 ソリフェナシン含有組成物
KR101836467B1 (ko) * 2004-03-25 2018-03-08 아스텔라스세이야쿠 가부시키가이샤 솔리페나신 또는 그의 염의 고형 제제용 조성물
CN1934109B (zh) * 2004-03-25 2010-06-23 安斯泰来制药株式会社 用于固体制剂的索非那新或其盐的组合物
WO2006035280A1 (fr) * 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Antagonistes des recepteurs muscariniques
US20090105221A1 (en) * 2004-09-29 2009-04-23 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
JP4636445B2 (ja) * 2004-12-27 2011-02-23 アステラス製薬株式会社 ソリフェナシンまたはその塩の安定な粒子状医薬組成物
WO2006070735A1 (fr) * 2004-12-27 2006-07-06 Astellas Pharma Inc. Préparation pharmaceutique granulaire stable de solifénacine ou de son sel
CA2599158C (fr) * 2005-02-25 2011-01-25 Astellas Pharma Inc. Agent pharmaceutique comprenant de la solifenacine
JP3701964B1 (ja) * 2005-03-08 2005-10-05 アステラス製薬株式会社 キヌクリジン誘導体の新規な塩
EP1904495A2 (fr) * 2005-07-11 2008-04-02 Ranbaxy Laboratories Limited Antagonistes des recepteurs muscariniques
US7815939B2 (en) 2005-07-20 2010-10-19 Astellas Pharma Inc. Coated fine particles containing drug for intrabuccally fast disintegrating dosage forms
BRPI0617674A2 (pt) 2005-10-19 2011-08-02 Ranbaxy Lab Ltd composições farmacêuticas e seus usos
CA2630846A1 (fr) * 2005-12-21 2007-07-05 Teva Pharmaceutical Industries Ltd. Procedes de preparation de solifenacine
CZ300699B6 (cs) * 2006-06-21 2009-07-22 Zentiva, A. S. Zpusob prípravy solifenacinu
US20090326230A1 (en) * 2006-07-19 2009-12-31 Dr. Reddy's Laboratories Ltd. Process for preparing solifenacin and its salts
ES2298049B1 (es) 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
EP2043639A2 (fr) * 2006-07-24 2009-04-08 Teva Pharmaceutical Industries Ltd. Procédés de préparation de forme polymorphes de succinate de solifénacine
US20080091023A1 (en) * 2006-08-03 2008-04-17 Nurit Perlman Processes for optical resolution of 1-phenyl-1,2,3,4-tetrahydroisoquinoline
TW200825084A (en) * 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
EP2102200A2 (fr) * 2006-11-22 2009-09-23 Medichem, S.A. Procédé perfectionné pour la synthèse de solifénacine
CZ300692B6 (cs) * 2006-12-22 2009-07-15 Zentiva, A. S. Zpusob prípravy solifenacinu
AR066206A1 (es) * 2007-03-30 2009-08-05 Medichem Sa Proceso para la sintesis de solifenacina
US20090099365A1 (en) * 2007-07-13 2009-04-16 Nurit Perlman Processes for solifenacin preparation
JPWO2009013846A1 (ja) * 2007-07-20 2010-10-07 アステラス製薬株式会社 前立腺肥大に伴う下部尿路症状の改善用医薬組成物
EP2018850A1 (fr) * 2007-07-24 2009-01-28 Ratiopharm GmbH Composition pharmaceutique comportant de la solifénacine ou sel acceptable pharmaceutiquement
CA2704298C (fr) 2007-11-02 2015-07-21 Astellas Pharma Inc. Composition pharmaceutique pour traiter une vessie hyperactive
WO2009073203A1 (fr) * 2007-12-04 2009-06-11 Amgen Inc. Ligands du récepteur trp-m8 et leur utilisation dans des traitements
EP2229387A1 (fr) * 2007-12-04 2010-09-22 Cadila Healthcare Limited Procédé de préparation d'une solifénacine base de pureté chimique et de pureté chirale et de ses sels
ITMI20080195A1 (it) 2008-02-08 2009-08-09 Dipharma Francis Srl Procedimento per la preparazione di solifenacin
EP2100598A1 (fr) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Composition à inhaler comprenant aclidinium pour le traitement de l'asthme et de maladies respiratoires obstructives chroniques
EP2100599A1 (fr) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Composition à inhaler comprenant aclidinium pour le traitement de l'asthme et de maladies respiratoires obstructives chroniques
US8404701B2 (en) 2008-03-27 2013-03-26 Chase Pharmaceuticals Corporation Use and composition for treating dementia
PL385264A1 (pl) 2008-05-23 2009-12-07 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania enancjomerycznie czystej (S)-1-fenylo-1, 2, 3, 4-tetrahydroizochinoliny
PL385265A1 (pl) * 2008-05-23 2009-12-07 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania solifenacyny i/lub jej soli o wysokiej czystości farmaceutycznej
SI3067353T1 (en) 2008-07-29 2018-03-30 Krka, D.D., Novo Mesto Process for the preparation of solifenacin salts and their inclusion in pharmaceutical dosage forms
EP2181707A1 (fr) 2008-11-04 2010-05-05 Astellas Ireland Co., Ltd. Utilisation combinée d'un antagoniste de récepteur alpha-adrénergique et d'un agent anti-muscarinique
NZ594311A (en) * 2009-02-04 2013-05-31 Astellas Pharma Inc Pharmaceutical composition comprising tamsulosin and solifenacin for oral administration
PL2406257T3 (pl) 2009-03-09 2020-01-31 Megafine Pharma (P) Ltd. Nowy sposób wytwarzania solifenacyny i jej nowy produkt pośredni
JP4816828B2 (ja) 2009-03-30 2011-11-16 アステラス製薬株式会社 ソリフェナシン非晶質体を含有した固形医薬組成物
WO2011048607A1 (fr) 2009-09-25 2011-04-28 Cadila Healthcare Limited Procédés de préparation de solifénacine ou d'un de ses sels
PL234208B1 (pl) 2010-01-18 2020-01-31 Zakl Farmaceutyczne Polpharma Spolka Akcyjna Sposób wytwarzania bursztynianu solifenacyny
ES2604705T3 (es) 2010-03-31 2017-03-08 Ono Pharmaceutical Co., Ltd. Agente preventivo y/o remedio para el síndrome mano-pie
WO2011137054A1 (fr) 2010-04-30 2011-11-03 Merck Sharp & Dohme Corp. Nouveaux agonistes du récepteur bêta 3 adrénergique
BR112012029461A2 (pt) 2010-05-19 2017-03-01 Astellas Pharma Inc composição farmacêutica contendo solifenacina
US8772491B2 (en) 2010-06-28 2014-07-08 Aurobindo Pharma Ltd Process for the preparation of solifenacin succinate
SI2590973T1 (sl) 2010-07-05 2017-01-31 Crystal Pharma, S.A.U. Soli solifenacina
CA2817336A1 (fr) 2010-11-11 2012-05-18 Hexal Ag Succinate de solifenacine cristallin
EP2510928A1 (fr) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium pour l'amélioration du sommeil des patients avec des maldadies respiratoires
EP3167885A1 (fr) 2011-05-10 2017-05-17 TheraVida, Inc. Combinaisons de solifénacine et pilocarpine pour le traitement d'une vessie hyperactive
US20140228575A1 (en) 2011-06-22 2014-08-14 Isochem Process for the Preparation of Solifenacin and Salts Thereof
KR101365849B1 (ko) 2012-03-28 2014-02-24 경동제약 주식회사 솔리페나신 또는 그의 염의 제조방법 및 이에 사용되는 신규 중간체
WO2014005601A1 (fr) 2012-07-02 2014-01-09 Pharmathen S.A. Procédé pour la préparation de solifénacine ou d'un de ses sels
EP2891493A4 (fr) 2012-08-31 2016-05-18 Astellas Pharma Inc Composition médicale administrée par voie orale
AU2013312749B2 (en) 2012-09-05 2018-01-18 Chase Pharmaceuticals Corporation Anticholinergic neuroprotective composition and methods
CN103787969B (zh) 2012-10-30 2016-07-06 上海京新生物医药有限公司 一种(1s)-1-苯基-3,4-二氢-2（1h）-异喹啉甲酸酯的制备方法
TW201427977A (zh) * 2012-12-06 2014-07-16 Chiesi Farma Spa 具有蕈毒鹼受體拮抗劑及β２腎上腺素受體致效劑活性之化合物
EP2778167A1 (fr) 2013-03-11 2014-09-17 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Composition pharmaceutique comprenant solifenacin ou l'un de ses sels pharmaceutiquement acceptable
RU2641285C2 (ru) * 2013-07-13 2018-01-17 Бэйцзин Фсвэлкам Текнолоджи Девелопмент Ко., Лтд Соединения хинина, способ их получения и их медицинское применение
US20170065589A1 (en) 2014-05-06 2017-03-09 Anthony G. Visco Methods of treating or preventing preterm labor
CN104592221A (zh) * 2015-01-26 2015-05-06 中山奕安泰医药科技有限公司 一种合成索非那新的工艺
KR20160146428A (ko) 2015-06-12 2016-12-21 한미정밀화학주식회사 솔리페나신 또는 그의 약학적으로 허용되는 염과 락토즈를 포함하는 안정한 무정형 솔리페나신 약학 조성물 및 그의 제조방법
KR102148414B1 (ko) 2017-05-15 2020-08-26 주식회사 서울제약 솔리페나신을 유효성분으로 하는 구강붕해필름
TW201927783A (zh) 2017-12-12 2019-07-16 美商阿爾庫達醫療公司 顆粒體蛋白前體調節劑及其使用方法
AU2020290485A1 (en) 2019-06-12 2021-12-02 Arkuda Therapeutics Progranulin modulators and methods of using the same
CN113200979A (zh) * 2021-04-13 2021-08-03 上海予君生物科技发展有限公司 一种琥珀酸索非那新的合成工艺

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2053451T3 (es) * 1986-01-07 1994-08-01 Beecham Group Plc Un procedimiento para la preparacion de un compuesto que tiene propiedades farmacologicas utiles.
IT1231238B (it) * 1987-09-21 1991-11-26 Angeli Inst Spa Derivati ammidinici
GB9023023D0 (en) * 1990-10-23 1990-12-05 Barlow Richard B Pharmaceutical compositions
GB9202443D0 (en) * 1992-02-05 1992-03-18 Fujisawa Pharmaceutical Co A novel substituted-acetamide compound and a process for the preparation thereof
JPH076635A (ja) * 1993-06-18 1995-01-10 Sony Corp 信号伝送ケーブル
AU7545894A (en) * 1993-09-02 1995-03-22 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
JPH07258250A (ja) * 1994-03-25 1995-10-09 Yamanouchi Pharmaceut Co Ltd エステル誘導体
EP1424021B1 (fr) * 2002-11-27 2006-09-13 Selmac S.r.l. Dispositif pour positionner et serrer des éléments préformés et machine équipée de ce dispositif

Also Published As

Publication number Publication date
TW305842B (fr) 1997-05-21
NO2017055I1 (no) 2017-11-06
NO2005016I1 (no) 2005-08-29
FR04C0032I2 (fr) 2005-10-21
RU2143432C1 (ru) 1999-12-27
DE122004000048I1 (de) 2005-04-21
AU4355396A (en) 1996-07-19
NO318026B1 (no) 2005-01-24
KR100386487B1 (ko) 2003-09-26
WO1996020194A1 (fr) 1996-07-04
DK0801067T3 (da) 2003-06-30
DE122004000048I2 (de) 2006-02-02
MX9704880A (es) 1997-10-31
JPH09508401A (ja) 1997-08-26
PL182344B1 (pl) 2001-12-31
NO973027L (no) 1997-08-28
KR987000303A (ko) 1998-03-30
NO973027D0 (no) 1997-06-27
EP0801067A1 (fr) 1997-10-15
NO2017055I2 (no) 2017-11-06
ES2193208T3 (es) 2003-11-01
EP0801067B1 (fr) 2003-03-05
AU695616B2 (en) 1998-08-20
EP0801067A4 (fr) 1998-03-11
NZ298144A (en) 1998-04-27
ATE233761T1 (de) 2003-03-15
LU91133I2 (fr) 2005-03-29
CA2208839A1 (fr) 1996-07-04
CN1045601C (zh) 1999-10-13
CA2208839C (fr) 2006-01-31
HUT77006A (hu) 1998-03-02
US6017927A (en) 2000-01-25
DE69529844D1 (de) 2003-04-10
CN1171109A (zh) 1998-01-21
PT801067E (pt) 2003-07-31
PL321019A1 (en) 1997-11-24
FI972775A0 (fi) 1997-06-27
NL300141I2 (nl) 2004-04-01
JP3014457B2 (ja) 2000-02-28
FI972775A (fi) 1997-08-22
DE69529844T2 (de) 2004-03-04
NO2005012I1 (no) 2005-06-06
NL300141I1 (nl) 2004-04-01
FR04C0032I1 (fr) 2005-02-11
HU223778B1 (hu) 2005-01-28
US6174896B1 (en) 2001-01-16
NO2005016I2 (no) 2008-02-11
FI115631B (fi) 2005-06-15

Similar Documents

Publication Publication Date Title
LU91133I9 (en) Novel quinuclidine derivatives and medicinal composition thereof
NO942953D0 (no) 11-benzaldoksimestradienderivater, fremgangsmåte for deres fremstilling smat legemddel inneholdende slike
AU673893B2 (en) New pyridothiadiazones, processes for their preparation and the pharmaceutical compositions which contain them
ATE109484T1 (de) Thienopyridin -derivative und diese enthaltende arzneimittel.
HUT59139A (en) Process for producing tricyclic compounds and antimicrobial pharmaceutical compositions comprising same
ZA921341B (en) 4-((2-benzothiazolyl)methylamino)-a-(3,4-difluorophenoxy) methyl)-1-piperidineethanol.
AU3559793A (en) New 3-aminochroman spiro compounds, processes for their preparation and pharmaceutical compositions containing them
NO910904L (no) Fremgangsmaate for fremstilling av en substituert aminforbindelse.
IL114646A (en) Pharmaceutical compositions containing phenylurea derivatives for inhibiting leukotriene biosynthesis
HUT68015A (en) New compound leustroducsin h, its preparation and pharmaceutical compositions containing them